Document is current
Any future updates will be listed below
-
Authors
Dai, Yi
Yao, Xiaoli
Zhu, Wenhua
Zhao, Yuying
Shang, Huifang
Chen, Juanjuan
Meng, Qiang
Liu, Yaling
Chen, Wanjin
Yu, Liqiang
Shen, Lu
Hong, Daojun
Chen, Ken
Zhang, Li
Mai, Maerhaba
Cui, Liying
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05618379 at ClinicalTrials.govDocuments that mention this clinical trial
Effectiveness and Safety of Nusinersen Among Adults with 5q-Spinal Muscular Atrophy: A Multicenter Disease Registry in China
https://doi.org/10.1007/s12325-025-03475-2
-
Funding
Funding for this research was provided by:
Biogen
- License Information
-
More Information
Article History
Received: 15 September 2025
Accepted: 11 December 2025
First Online: 29 December 2025
Declarations
:
: Li Zhang and Maerhaba Mai are employees of Biogen and may hold stock in Biogen. Ken Chen is an employee of IQVIA. Yi Dai, Xiaoli Yao, Wenhua Zhu, Yuying Zhao, Huifang Shang, Juanjuan Chen, Qiang Meng, Yaling Liu, Wanjin Chen, Liqiang Yu, Lu Shen, Daojun Hong, and Liying Cui declare that they have no conflict of interests.
: Study protocol was approved by the ethics committees of each participating site. The study was conducted in accordance with the Declaration of Helsinki. Informed consents of all participants (or their legally authorized guardians) were obtained in accordance with local institutions’ regulations.
